Global Oncolytic Virus Therapy Supply, Demand and Key Producers, 2026-2032
The global Oncolytic Virus Therapy market size is expected to reach $ 236 million by 2032, rising at a market growth of 10.1% CAGR during the forecast period (2026-2032).
Oncolytic Virus Therapy is an innovative cancer treatment approach that employs genetically modified viruses to selectively infect and destroy tumor cells while activating the host’s immune system to launch a systemic anti-tumor response. These viruses induce direct oncolysis and stimulate immunogenic cell death, positioning them as a pivotal class in immuno-oncology. Unlike chemotherapy or radiotherapy, this modality offers enhanced tumor selectivity, reduced toxicity, and strong synergistic potential when combined with immune checkpoint inhibitors. Products like Talimogene laherparepvec (T-VEC) have received FDA approval, showing promising efficacy in melanoma and drawing increasing R&D and commercial attention from global pharmaceutical companies.
With breakthroughs in immuno-oncology and the advancement of precision medicine, oncolytic virus therapy is entering a period of rapid growth. Global regulatory bodies are encouraging innovation through frameworks like the FDA's Breakthrough Therapy designation and the EU’s PRIME program, facilitating clinical acceleration and early commercialization. The increasing incidence of cancer, particularly advanced solid tumors, underscores the unmet demand for novel mechanisms of action. Furthermore, leading biopharmaceutical companies are actively investing in M&A and strategic partnerships in this space, significantly expanding their pipelines. Since 2023, several oncolytic virus candidates have advanced into Phase III trials, marking a clear shift toward industrial scalability.
Despite promising prospects, several key challenges persist in the development of oncolytic virus therapies. Efficient in vivo delivery and tumor-specific targeting remain technical hurdles, especially in patients with immunosuppressive microenvironments or rapid viral clearance. Clinical trials are resource-intensive, requiring long timelines, significant funding, and multidisciplinary collaboration spanning virology, immunology, and translational medicine. Safety concerns also linger, including risks of off-target infection and systemic inflammation. Additionally, the industry still lacks a broad base of commercially successful precedents, leading to cautious investment sentiment and uncertain return on investment timelines.
The downstream demand for innovative cancer therapies is rapidly rising, with oncolytic viruses increasingly recognized as critical components of next-generation immunotherapy combinations. In difficult-to-treat tumors such as glioblastoma, pancreatic cancer, and bladder cancer, preliminary data indicates enhanced efficacy when combined with checkpoint inhibitors like PD-1/PD-L1. Clinical practitioners and patient communities alike are showing growing interest. Moreover, the Asia-Pacific region is emerging as a significant growth engine, with supportive policies and increasing clinical trial activity in countries like China, Japan, and South Korea, paving the way for future regional commercialization strategies.
This report studies the global Oncolytic Virus Therapy demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oncolytic Virus Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oncolytic Virus Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oncolytic Virus Therapy total market, 2021-2032, (USD Million)
Global Oncolytic Virus Therapy total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Oncolytic Virus Therapy total market, key domestic companies, and share, (USD Million)
Global Oncolytic Virus Therapy revenue by player, revenue and market share 2021-2026, (USD Million)
Global Oncolytic Virus Therapy total market by Type, CAGR, 2021-2032, (USD Million)
Global Oncolytic Virus Therapy total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Oncolytic Virus Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, RIGVIR Group, 3s-guojian, Shuanghe Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Oncolytic Virus Therapy market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Oncolytic Virus Therapy Market, By Region:
1. How big is the global Oncolytic Virus Therapy market?
2. What is the demand of the global Oncolytic Virus Therapy market?
3. What is the year over year growth of the global Oncolytic Virus Therapy market?
4. What is the total value of the global Oncolytic Virus Therapy market?
5. Who are the Major Players in the global Oncolytic Virus Therapy market?
6. What are the growth factors driving the market demand?
Oncolytic Virus Therapy is an innovative cancer treatment approach that employs genetically modified viruses to selectively infect and destroy tumor cells while activating the host’s immune system to launch a systemic anti-tumor response. These viruses induce direct oncolysis and stimulate immunogenic cell death, positioning them as a pivotal class in immuno-oncology. Unlike chemotherapy or radiotherapy, this modality offers enhanced tumor selectivity, reduced toxicity, and strong synergistic potential when combined with immune checkpoint inhibitors. Products like Talimogene laherparepvec (T-VEC) have received FDA approval, showing promising efficacy in melanoma and drawing increasing R&D and commercial attention from global pharmaceutical companies.
With breakthroughs in immuno-oncology and the advancement of precision medicine, oncolytic virus therapy is entering a period of rapid growth. Global regulatory bodies are encouraging innovation through frameworks like the FDA's Breakthrough Therapy designation and the EU’s PRIME program, facilitating clinical acceleration and early commercialization. The increasing incidence of cancer, particularly advanced solid tumors, underscores the unmet demand for novel mechanisms of action. Furthermore, leading biopharmaceutical companies are actively investing in M&A and strategic partnerships in this space, significantly expanding their pipelines. Since 2023, several oncolytic virus candidates have advanced into Phase III trials, marking a clear shift toward industrial scalability.
Despite promising prospects, several key challenges persist in the development of oncolytic virus therapies. Efficient in vivo delivery and tumor-specific targeting remain technical hurdles, especially in patients with immunosuppressive microenvironments or rapid viral clearance. Clinical trials are resource-intensive, requiring long timelines, significant funding, and multidisciplinary collaboration spanning virology, immunology, and translational medicine. Safety concerns also linger, including risks of off-target infection and systemic inflammation. Additionally, the industry still lacks a broad base of commercially successful precedents, leading to cautious investment sentiment and uncertain return on investment timelines.
The downstream demand for innovative cancer therapies is rapidly rising, with oncolytic viruses increasingly recognized as critical components of next-generation immunotherapy combinations. In difficult-to-treat tumors such as glioblastoma, pancreatic cancer, and bladder cancer, preliminary data indicates enhanced efficacy when combined with checkpoint inhibitors like PD-1/PD-L1. Clinical practitioners and patient communities alike are showing growing interest. Moreover, the Asia-Pacific region is emerging as a significant growth engine, with supportive policies and increasing clinical trial activity in countries like China, Japan, and South Korea, paving the way for future regional commercialization strategies.
This report studies the global Oncolytic Virus Therapy demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Oncolytic Virus Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oncolytic Virus Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Oncolytic Virus Therapy total market, 2021-2032, (USD Million)
Global Oncolytic Virus Therapy total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Oncolytic Virus Therapy total market, key domestic companies, and share, (USD Million)
Global Oncolytic Virus Therapy revenue by player, revenue and market share 2021-2026, (USD Million)
Global Oncolytic Virus Therapy total market by Type, CAGR, 2021-2032, (USD Million)
Global Oncolytic Virus Therapy total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Oncolytic Virus Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, RIGVIR Group, 3s-guojian, Shuanghe Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Oncolytic Virus Therapy market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Oncolytic Virus Therapy Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- HSV-based Oncolytic Viruses
- Adenoviruses-based Oncolytic Viruses
- Vaccinia Virus-based Oncolytic Viruses
- Vesicular Stomatitis Virus-based Oncolytic Viruses
- Newcastle Disease Virus-based Oncolytic Viruses
- Melanoma
- Prostate Cancer
- Breast Cancer
- Ovarian Cancer
- Others
- Amgen
- RIGVIR Group
- 3s-guojian
- Shuanghe Pharmaceutical
1. How big is the global Oncolytic Virus Therapy market?
2. What is the demand of the global Oncolytic Virus Therapy market?
3. What is the year over year growth of the global Oncolytic Virus Therapy market?
4. What is the total value of the global Oncolytic Virus Therapy market?
5. Who are the Major Players in the global Oncolytic Virus Therapy market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Oncolytic Virus Therapy Introduction
1.2 World Oncolytic Virus Therapy Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Oncolytic Virus Therapy Total Market by Region (by Headquarter Location)
1.3.1 World Oncolytic Virus Therapy Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.3 China Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.4 Europe Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.5 Japan Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.6 South Korea Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.7 ASEAN Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.8 India Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oncolytic Virus Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Oncolytic Virus Therapy Consumption Value (2021-2032)
2.2 World Oncolytic Virus Therapy Consumption Value by Region
2.2.1 World Oncolytic Virus Therapy Consumption Value by Region (2021-2026)
2.2.2 World Oncolytic Virus Therapy Consumption Value Forecast by Region (2027-2032)
2.3 United States Oncolytic Virus Therapy Consumption Value (2021-2032)
2.4 China Oncolytic Virus Therapy Consumption Value (2021-2032)
2.5 Europe Oncolytic Virus Therapy Consumption Value (2021-2032)
2.6 Japan Oncolytic Virus Therapy Consumption Value (2021-2032)
2.7 South Korea Oncolytic Virus Therapy Consumption Value (2021-2032)
2.8 ASEAN Oncolytic Virus Therapy Consumption Value (2021-2032)
2.9 India Oncolytic Virus Therapy Consumption Value (2021-2032)
3 WORLD ONCOLYTIC VIRUS THERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World Oncolytic Virus Therapy Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Oncolytic Virus Therapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Oncolytic Virus Therapy in 2025
3.2.3 Global Concentration Ratios (CR8) for Oncolytic Virus Therapy in 2025
3.3 Oncolytic Virus Therapy Company Evaluation Quadrant
3.4 Oncolytic Virus Therapy Market: Overall Company Footprint Analysis
3.4.1 Oncolytic Virus Therapy Market: Region Footprint
3.4.2 Oncolytic Virus Therapy Market: Company Product Type Footprint
3.4.3 Oncolytic Virus Therapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Oncolytic Virus Therapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Oncolytic Virus Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Oncolytic Virus Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Oncolytic Virus Therapy Consumption Value Comparison
4.2.1 United States VS China: Oncolytic Virus Therapy Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Oncolytic Virus Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Oncolytic Virus Therapy Companies and Market Share, 2021-2026
4.3.1 United States Based Oncolytic Virus Therapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Oncolytic Virus Therapy Revenue, (2021-2026)
4.4 China Based Companies Oncolytic Virus Therapy Revenue and Market Share, 2021-2026
4.4.1 China Based Oncolytic Virus Therapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Oncolytic Virus Therapy Revenue, (2021-2026)
4.5 Rest of World Based Oncolytic Virus Therapy Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Oncolytic Virus Therapy Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Oncolytic Virus Therapy Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Oncolytic Virus Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 HSV-based Oncolytic Viruses
5.2.2 Adenoviruses-based Oncolytic Viruses
5.2.3 Vaccinia Virus-based Oncolytic Viruses
5.2.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
5.2.5 Newcastle Disease Virus-based Oncolytic Viruses
5.3 Market Segment by Type
5.3.1 World Oncolytic Virus Therapy Market Size by Type (2021-2026)
5.3.2 World Oncolytic Virus Therapy Market Size by Type (2027-2032)
5.3.3 World Oncolytic Virus Therapy Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Oncolytic Virus Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 Melanoma
6.2.2 Prostate Cancer
6.2.3 Breast Cancer
6.2.4 Ovarian Cancer
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Oncolytic Virus Therapy Market Size by Application (2021-2026)
6.3.2 World Oncolytic Virus Therapy Market Size by Application (2027-2032)
6.3.3 World Oncolytic Virus Therapy Market Size Market Share by Application (2021-2032)
7 COMPANY PROFILES
7.1 Amgen
7.1.1 Amgen Details
7.1.2 Amgen Major Business
7.1.3 Amgen Oncolytic Virus Therapy Product and Services
7.1.4 Amgen Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026)
7.1.5 Amgen Recent Developments/Updates
7.1.6 Amgen Competitive Strengths & Weaknesses
7.2 RIGVIR Group
7.2.1 RIGVIR Group Details
7.2.2 RIGVIR Group Major Business
7.2.3 RIGVIR Group Oncolytic Virus Therapy Product and Services
7.2.4 RIGVIR Group Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026)
7.2.5 RIGVIR Group Recent Developments/Updates
7.2.6 RIGVIR Group Competitive Strengths & Weaknesses
7.3 3s-guojian
7.3.1 3s-guojian Details
7.3.2 3s-guojian Major Business
7.3.3 3s-guojian Oncolytic Virus Therapy Product and Services
7.3.4 3s-guojian Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026)
7.3.5 3s-guojian Recent Developments/Updates
7.3.6 3s-guojian Competitive Strengths & Weaknesses
7.4 Shuanghe Pharmaceutical
7.4.1 Shuanghe Pharmaceutical Details
7.4.2 Shuanghe Pharmaceutical Major Business
7.4.3 Shuanghe Pharmaceutical Oncolytic Virus Therapy Product and Services
7.4.4 Shuanghe Pharmaceutical Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026)
7.4.5 Shuanghe Pharmaceutical Recent Developments/Updates
7.4.6 Shuanghe Pharmaceutical Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Oncolytic Virus Therapy Industry Chain
8.2 Oncolytic Virus Therapy Upstream Analysis
8.3 Oncolytic Virus Therapy Midstream Analysis
8.4 Oncolytic Virus Therapy Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Oncolytic Virus Therapy Introduction
1.2 World Oncolytic Virus Therapy Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Oncolytic Virus Therapy Total Market by Region (by Headquarter Location)
1.3.1 World Oncolytic Virus Therapy Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.3 China Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.4 Europe Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.5 Japan Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.6 South Korea Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.7 ASEAN Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.3.8 India Based Company Oncolytic Virus Therapy Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Oncolytic Virus Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Oncolytic Virus Therapy Consumption Value (2021-2032)
2.2 World Oncolytic Virus Therapy Consumption Value by Region
2.2.1 World Oncolytic Virus Therapy Consumption Value by Region (2021-2026)
2.2.2 World Oncolytic Virus Therapy Consumption Value Forecast by Region (2027-2032)
2.3 United States Oncolytic Virus Therapy Consumption Value (2021-2032)
2.4 China Oncolytic Virus Therapy Consumption Value (2021-2032)
2.5 Europe Oncolytic Virus Therapy Consumption Value (2021-2032)
2.6 Japan Oncolytic Virus Therapy Consumption Value (2021-2032)
2.7 South Korea Oncolytic Virus Therapy Consumption Value (2021-2032)
2.8 ASEAN Oncolytic Virus Therapy Consumption Value (2021-2032)
2.9 India Oncolytic Virus Therapy Consumption Value (2021-2032)
3 WORLD ONCOLYTIC VIRUS THERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World Oncolytic Virus Therapy Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Oncolytic Virus Therapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Oncolytic Virus Therapy in 2025
3.2.3 Global Concentration Ratios (CR8) for Oncolytic Virus Therapy in 2025
3.3 Oncolytic Virus Therapy Company Evaluation Quadrant
3.4 Oncolytic Virus Therapy Market: Overall Company Footprint Analysis
3.4.1 Oncolytic Virus Therapy Market: Region Footprint
3.4.2 Oncolytic Virus Therapy Market: Company Product Type Footprint
3.4.3 Oncolytic Virus Therapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Oncolytic Virus Therapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Oncolytic Virus Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Oncolytic Virus Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Oncolytic Virus Therapy Consumption Value Comparison
4.2.1 United States VS China: Oncolytic Virus Therapy Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Oncolytic Virus Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Oncolytic Virus Therapy Companies and Market Share, 2021-2026
4.3.1 United States Based Oncolytic Virus Therapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Oncolytic Virus Therapy Revenue, (2021-2026)
4.4 China Based Companies Oncolytic Virus Therapy Revenue and Market Share, 2021-2026
4.4.1 China Based Oncolytic Virus Therapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Oncolytic Virus Therapy Revenue, (2021-2026)
4.5 Rest of World Based Oncolytic Virus Therapy Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Oncolytic Virus Therapy Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Oncolytic Virus Therapy Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Oncolytic Virus Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 HSV-based Oncolytic Viruses
5.2.2 Adenoviruses-based Oncolytic Viruses
5.2.3 Vaccinia Virus-based Oncolytic Viruses
5.2.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
5.2.5 Newcastle Disease Virus-based Oncolytic Viruses
5.3 Market Segment by Type
5.3.1 World Oncolytic Virus Therapy Market Size by Type (2021-2026)
5.3.2 World Oncolytic Virus Therapy Market Size by Type (2027-2032)
5.3.3 World Oncolytic Virus Therapy Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Oncolytic Virus Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 Melanoma
6.2.2 Prostate Cancer
6.2.3 Breast Cancer
6.2.4 Ovarian Cancer
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Oncolytic Virus Therapy Market Size by Application (2021-2026)
6.3.2 World Oncolytic Virus Therapy Market Size by Application (2027-2032)
6.3.3 World Oncolytic Virus Therapy Market Size Market Share by Application (2021-2032)
7 COMPANY PROFILES
7.1 Amgen
7.1.1 Amgen Details
7.1.2 Amgen Major Business
7.1.3 Amgen Oncolytic Virus Therapy Product and Services
7.1.4 Amgen Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026)
7.1.5 Amgen Recent Developments/Updates
7.1.6 Amgen Competitive Strengths & Weaknesses
7.2 RIGVIR Group
7.2.1 RIGVIR Group Details
7.2.2 RIGVIR Group Major Business
7.2.3 RIGVIR Group Oncolytic Virus Therapy Product and Services
7.2.4 RIGVIR Group Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026)
7.2.5 RIGVIR Group Recent Developments/Updates
7.2.6 RIGVIR Group Competitive Strengths & Weaknesses
7.3 3s-guojian
7.3.1 3s-guojian Details
7.3.2 3s-guojian Major Business
7.3.3 3s-guojian Oncolytic Virus Therapy Product and Services
7.3.4 3s-guojian Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026)
7.3.5 3s-guojian Recent Developments/Updates
7.3.6 3s-guojian Competitive Strengths & Weaknesses
7.4 Shuanghe Pharmaceutical
7.4.1 Shuanghe Pharmaceutical Details
7.4.2 Shuanghe Pharmaceutical Major Business
7.4.3 Shuanghe Pharmaceutical Oncolytic Virus Therapy Product and Services
7.4.4 Shuanghe Pharmaceutical Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026)
7.4.5 Shuanghe Pharmaceutical Recent Developments/Updates
7.4.6 Shuanghe Pharmaceutical Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Oncolytic Virus Therapy Industry Chain
8.2 Oncolytic Virus Therapy Upstream Analysis
8.3 Oncolytic Virus Therapy Midstream Analysis
8.4 Oncolytic Virus Therapy Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Oncolytic Virus Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Oncolytic Virus Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Oncolytic Virus Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Oncolytic Virus Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Oncolytic Virus Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Oncolytic Virus Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Oncolytic Virus Therapy Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Oncolytic Virus Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Oncolytic Virus Therapy Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Oncolytic Virus Therapy Players in 2025
Table 12. World Oncolytic Virus Therapy Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Oncolytic Virus Therapy Company Evaluation Quadrant
Table 14. Head Office of Key Oncolytic Virus Therapy Players
Table 15. Oncolytic Virus Therapy Market: Company Product Type Footprint
Table 16. Oncolytic Virus Therapy Market: Company Product Application Footprint
Table 17. Oncolytic Virus Therapy Mergers & Acquisitions Activity
Table 18. United States VS China Oncolytic Virus Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Oncolytic Virus Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Oncolytic Virus Therapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies Oncolytic Virus Therapy Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Oncolytic Virus Therapy Revenue Market Share (2021-2026)
Table 23. China Based Oncolytic Virus Therapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies Oncolytic Virus Therapy Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Oncolytic Virus Therapy Revenue Market Share (2021-2026)
Table 26. Rest of World Based Oncolytic Virus Therapy Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Oncolytic Virus Therapy Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Oncolytic Virus Therapy Revenue Market Share (2021-2026)
Table 29. World Oncolytic Virus Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Oncolytic Virus Therapy Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Oncolytic Virus Therapy Market Size by Type (2027-2032) & (USD Million)
Table 32. World Oncolytic Virus Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 33. World Oncolytic Virus Therapy Market Size by Application (2021-2026) & (USD Million)
Table 34. World Oncolytic Virus Therapy Market Size by Application (2027-2032) & (USD Million)
Table 35. Amgen Basic Information, Manufacturing Base and Competitors
Table 36. Amgen Major Business
Table 37. Amgen Oncolytic Virus Therapy Product and Services
Table 38. Amgen Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 39. Amgen Recent Developments/Updates
Table 40. Amgen Competitive Strengths & Weaknesses
Table 41. RIGVIR Group Basic Information, Manufacturing Base and Competitors
Table 42. RIGVIR Group Major Business
Table 43. RIGVIR Group Oncolytic Virus Therapy Product and Services
Table 44. RIGVIR Group Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. RIGVIR Group Recent Developments/Updates
Table 46. RIGVIR Group Competitive Strengths & Weaknesses
Table 47. 3s-guojian Basic Information, Manufacturing Base and Competitors
Table 48. 3s-guojian Major Business
Table 49. 3s-guojian Oncolytic Virus Therapy Product and Services
Table 50. 3s-guojian Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. 3s-guojian Recent Developments/Updates
Table 52. 3s-guojian Competitive Strengths & Weaknesses
Table 53. Shuanghe Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 54. Shuanghe Pharmaceutical Major Business
Table 55. Shuanghe Pharmaceutical Oncolytic Virus Therapy Product and Services
Table 56. Shuanghe Pharmaceutical Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Shuanghe Pharmaceutical Recent Developments/Updates
Table 58. Shuanghe Pharmaceutical Competitive Strengths & Weaknesses
Table 59. Global Key Players of Oncolytic Virus Therapy Upstream (Raw Materials)
Table 60. Global Oncolytic Virus Therapy Typical Customers
Table 1. World Oncolytic Virus Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Oncolytic Virus Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Oncolytic Virus Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Oncolytic Virus Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Oncolytic Virus Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Oncolytic Virus Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Oncolytic Virus Therapy Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Oncolytic Virus Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Oncolytic Virus Therapy Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Oncolytic Virus Therapy Players in 2025
Table 12. World Oncolytic Virus Therapy Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Oncolytic Virus Therapy Company Evaluation Quadrant
Table 14. Head Office of Key Oncolytic Virus Therapy Players
Table 15. Oncolytic Virus Therapy Market: Company Product Type Footprint
Table 16. Oncolytic Virus Therapy Market: Company Product Application Footprint
Table 17. Oncolytic Virus Therapy Mergers & Acquisitions Activity
Table 18. United States VS China Oncolytic Virus Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Oncolytic Virus Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Oncolytic Virus Therapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies Oncolytic Virus Therapy Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Oncolytic Virus Therapy Revenue Market Share (2021-2026)
Table 23. China Based Oncolytic Virus Therapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies Oncolytic Virus Therapy Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Oncolytic Virus Therapy Revenue Market Share (2021-2026)
Table 26. Rest of World Based Oncolytic Virus Therapy Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Oncolytic Virus Therapy Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Oncolytic Virus Therapy Revenue Market Share (2021-2026)
Table 29. World Oncolytic Virus Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Oncolytic Virus Therapy Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Oncolytic Virus Therapy Market Size by Type (2027-2032) & (USD Million)
Table 32. World Oncolytic Virus Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 33. World Oncolytic Virus Therapy Market Size by Application (2021-2026) & (USD Million)
Table 34. World Oncolytic Virus Therapy Market Size by Application (2027-2032) & (USD Million)
Table 35. Amgen Basic Information, Manufacturing Base and Competitors
Table 36. Amgen Major Business
Table 37. Amgen Oncolytic Virus Therapy Product and Services
Table 38. Amgen Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 39. Amgen Recent Developments/Updates
Table 40. Amgen Competitive Strengths & Weaknesses
Table 41. RIGVIR Group Basic Information, Manufacturing Base and Competitors
Table 42. RIGVIR Group Major Business
Table 43. RIGVIR Group Oncolytic Virus Therapy Product and Services
Table 44. RIGVIR Group Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. RIGVIR Group Recent Developments/Updates
Table 46. RIGVIR Group Competitive Strengths & Weaknesses
Table 47. 3s-guojian Basic Information, Manufacturing Base and Competitors
Table 48. 3s-guojian Major Business
Table 49. 3s-guojian Oncolytic Virus Therapy Product and Services
Table 50. 3s-guojian Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. 3s-guojian Recent Developments/Updates
Table 52. 3s-guojian Competitive Strengths & Weaknesses
Table 53. Shuanghe Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 54. Shuanghe Pharmaceutical Major Business
Table 55. Shuanghe Pharmaceutical Oncolytic Virus Therapy Product and Services
Table 56. Shuanghe Pharmaceutical Oncolytic Virus Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Shuanghe Pharmaceutical Recent Developments/Updates
Table 58. Shuanghe Pharmaceutical Competitive Strengths & Weaknesses
Table 59. Global Key Players of Oncolytic Virus Therapy Upstream (Raw Materials)
Table 60. Global Oncolytic Virus Therapy Typical Customers
LIST OF FIGURES
Figure 1. Oncolytic Virus Therapy Picture
Figure 2. World Oncolytic Virus Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Oncolytic Virus Therapy Total Revenue (2021-2032) & (USD Million)
Figure 4. World Oncolytic Virus Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Oncolytic Virus Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 13. Oncolytic Virus Therapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 16. World Oncolytic Virus Therapy Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 18. China Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 23. India Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Oncolytic Virus Therapy by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oncolytic Virus Therapy Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oncolytic Virus Therapy Markets in 2025
Figure 27. United States VS China: Oncolytic Virus Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Oncolytic Virus Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Oncolytic Virus Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Oncolytic Virus Therapy Market Size Market Share by Type in 2025
Figure 31. HSV-based Oncolytic Viruses
Figure 32. Adenoviruses-based Oncolytic Viruses
Figure 33. Vaccinia Virus-based Oncolytic Viruses
Figure 34. Vesicular Stomatitis Virus-based Oncolytic Viruses
Figure 35. Newcastle Disease Virus-based Oncolytic Viruses
Figure 36. World Oncolytic Virus Therapy Market Size Market Share by Type (2021-2032)
Figure 37. World Oncolytic Virus Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 38. World Oncolytic Virus Therapy Market Size Market Share by Application in 2025
Figure 39. Melanoma
Figure 40. Prostate Cancer
Figure 41. Breast Cancer
Figure 42. Ovarian Cancer
Figure 43. Others
Figure 44. World Oncolytic Virus Therapy Market Size Market Share by Application (2021-2032)
Figure 45. Oncolytic Virus Therapy Industrial Chain
Figure 46. Methodology
Figure 47. Research Process and Data Source
Figure 1. Oncolytic Virus Therapy Picture
Figure 2. World Oncolytic Virus Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Oncolytic Virus Therapy Total Revenue (2021-2032) & (USD Million)
Figure 4. World Oncolytic Virus Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Oncolytic Virus Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Oncolytic Virus Therapy Revenue (2021-2032) & (USD Million)
Figure 13. Oncolytic Virus Therapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 16. World Oncolytic Virus Therapy Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 18. China Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 23. India Oncolytic Virus Therapy Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Oncolytic Virus Therapy by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Oncolytic Virus Therapy Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Oncolytic Virus Therapy Markets in 2025
Figure 27. United States VS China: Oncolytic Virus Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Oncolytic Virus Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Oncolytic Virus Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Oncolytic Virus Therapy Market Size Market Share by Type in 2025
Figure 31. HSV-based Oncolytic Viruses
Figure 32. Adenoviruses-based Oncolytic Viruses
Figure 33. Vaccinia Virus-based Oncolytic Viruses
Figure 34. Vesicular Stomatitis Virus-based Oncolytic Viruses
Figure 35. Newcastle Disease Virus-based Oncolytic Viruses
Figure 36. World Oncolytic Virus Therapy Market Size Market Share by Type (2021-2032)
Figure 37. World Oncolytic Virus Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 38. World Oncolytic Virus Therapy Market Size Market Share by Application in 2025
Figure 39. Melanoma
Figure 40. Prostate Cancer
Figure 41. Breast Cancer
Figure 42. Ovarian Cancer
Figure 43. Others
Figure 44. World Oncolytic Virus Therapy Market Size Market Share by Application (2021-2032)
Figure 45. Oncolytic Virus Therapy Industrial Chain
Figure 46. Methodology
Figure 47. Research Process and Data Source
